Lymph Node-Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors.

T-cell receptor (TCR)-modified T-cell therapies have shown promise against solid tumors, but overall therapeutic benefits have been modest due in part to suboptimal T-cell persistence and activation in vivo, alongside potential tumor antigen escape. In this study, we demonstrate an approach to enhance the in vivo persistence and function of TCR T cells through combination with Amphiphile (AMP) vaccination including cognate TCR T peptides. AMP modification improves lymph node targeting of conjugated tumor immunogens and adjuvants, thereby coordinating a robust T cell-activating endogenous immune response.

Progress towards blue emitting MgO-ZnO-GaO nanocomposites synthesized by bio mediated route.

MgO-ZnO-GaO nanocomposites are synthesized by solution combustion method using Aloe Vera gel as a reducing agent to increase the efficiency of blue emission. The appearance of Bragg reflections corresponding to MgO, ZnO and GaO clearly indicates the formation of nanocomposites. The surface morphology consists irregular shape and sized NPs.

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using amphiphile (Amph) modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). We treated 25 patients (20 pancreatic and five colorectal) who were positive for minimal residual mKRAS disease (ctDNA and/or serum tumor antigen) after locoregional treatment in a phase 1 study of fixed-dose Amph-Peptides-2P and ascending-dose Amph-CpG-7909; study enrollment is complete with patient follow-up ongoing.

An innovative approach for estimating energy absorption buildup factors (EABF) with HVL and TVL.

The current study proposes an empirical formula for absorption buildup factors as a function of target thickness. The present formula produces absorption buildup factors of compounds and mixtures with simple inputs of linear attenuation coefficient (μ), tenth value layer (TVL) and half value layer (HVL) of interacting target for the atomic number region 29 < Z < 92 for the energies 0.2 MeV < E < 1.